Sahu, N., Stephan, J., Cruz, D. D., Merchant, M., Haley, B., Bourgon, R., . . . Settleman, J. (2016). Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs. Nature Portfolio.
Cita Chicago Style (17a ed.)Sahu, Nisebita, Jean-Philippe Stephan, Darlene Dela Cruz, Mark Merchant, Benjamin Haley, Richard Bourgon, Marie Classon, y Jeff Settleman. Functional Screening Implicates MiR-371-3p and Peroxiredoxin 6 in Reversible Tolerance to Cancer Drugs. Nature Portfolio, 2016.
Cita MLA (8a ed.)Sahu, Nisebita, et al. Functional Screening Implicates MiR-371-3p and Peroxiredoxin 6 in Reversible Tolerance to Cancer Drugs. Nature Portfolio, 2016.
Precaución: Estas citas no son 100% exactas.